Mark Esposito
Principal investigator, leads KAYOTHERA INC.
BiotechFounder
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2023First federal award
$1.1MFederal grants as PI3 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
3 awards · $1.1M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| May 24, 2023 | NIH | SBIR Phase I Development of first-in-class antagonists of the retinoid pathway as novel oral therapies for Type 2 Diabetes | $338K | KAYOTHERA INC |
| May 24, 2023 | NIH | SBIR Phase I Development of first-in-class antagonists of the retinoid pathway as novel oral therapies for Type 2 Diabetes | $338K | KAYOTHERA INC |
| May 3, 2023 | NIH | SBIR Phase I Development of first-in-class antagonists of the retinoid pathway as novel oral immunotherapies for solid cancers | $398K | KAYOTHERA INC |
1 patents as inventor
- US KAYOTHERA INC—
Matched by the first inventor’s name and the patent’s company.
Peer ranks
Federal funding#1,684
Awards as PI#822
Patents#273
Companies
- KAYOTHERA INCLeads (SEC Form D) · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.